Carob in the Pharmaceutical and Supplement Industry
Carob enters the pharmaceutical and supplement industry in two different ways: The carob gum obtained from the seed is investigated as an excipient in tablets and gels, while the D-pinitol found in pods is the subject of supplement products.
In this article, we discuss the place of the scale in pharmaceutical technology, why human studies on D-pinitol have shown different results from each other, and what should be considered in terms of legislation and quality in supplement products.
How Does Carob Meet the Pharmaceutical and Supplement Industry?
The place of carob in the pharmaceutical and supplement industry is usually described under a single heading; however, here are two completely different raw materials.
| Feature | Carob gamut | D-pinitol |
|---|---|---|
| Source of | Endosperm of the nucleus | The fleshy part of the pod (pulp) |
| Chemical structure | Galactomannan (large polysaccharide) | Inositol derivative small molecule |
| Role in the industry | Excipient: gel, matrix, consistency | Marketed as an active ingredient in supplement products |
| Basic question | How does it act in formulation? | Does it have a measurable effect on humans? |
Gum is not used for a health effect per se, but to create the physical structure of the drug or supplement. D-pinitol, on the other hand, is an ingredient marketed with the expectation of a direct physiological effect. For this reason, the evaluation criteria for the two raw materials are also different: In gum, technical performance and consistency are emphasized, while in D-pinitol, the strength of clinical evidence and the accuracy of the dose come to the fore.
What is Excipient and Why Does Carob Gum Gain Traction?
A drug or supplement tablet does not only consist of the active ingredient. The ingredients that maintain the shape of the tablet, determine when and how quickly the active ingredient will be released in the body, or provide consistency in liquid products are called excipients. Natural polysaccharides have long been researched in this field because they are biocompatible and biodegradable.
Dionísio and Grenha (2012), who compiled the biopharmaceutical applications of carob gum, define the high gel-forming capacity of the gum as its prominent feature. According to the review, the main reason for the increasing interest in gamma is that it can be used as an excipient that provides controlled release in tablets. When the gum comes into contact with water, it swells and forms a gel layer around the tablet; the active ingredient is released from this layer by spreading over time.
| Controlled release matrix | With its swelling feature, it contributes to the slower and more regular release of the active ingredient. |
| Synergy with xanthan gum | According to the review, the most effective synergy is achieved with xantane, resulting in a tight, heat-reversible gel; there is also a commercial tablet technology (TIMERx®) based on this duo. |
| Dispenser (disinfectant) use | It has been reported to be tried as a superdispersant in orally disintegrating tablets. |
| Microspheres | Controlled release trials were conducted in microspheres prepared with alginate. |
The same review also includes an important caveat: the results in this area are sometimes contradictory to each other, and the authors note that this may be due to differences between gamuts from different suppliers or other ingredients added to the formula (Dionísio and Grenha, 2012). This shows how critical the technical specification of the raw material is in pharmaceutical use.
Current Research: Hydrogels and Inhalation Administration
Pharmaceutical research into carob gum has expanded beyond conventional tablets in recent years. Sana et al.'s (2024) comprehensive review conveys that hydrogels prepared from the gum can be used as drug carriers and are suitable for the slow and sustained release of active ingredients. The same review highlights that the extraction method plays a crucial role in determining the viscosity and gel-forming properties of the gum.
Another remarkable study examines the usability of the gum in delivering powdered drugs to the lung. Pontes et al. (2025) characterized carob gum from three different suppliers, noting that most of the excipients used in inhalation products are not approved for this pathway. Commercial samples have been reported to show similar chemical and thermal profiles, do not markedly reduce cell viability in respiratory tract cells at realistic concentrations, and no allergic reactions have been observed when inhaled in mice. The authors consider these results as a basis for further investigation of the gum in the field of inhalation.
None of these studies mean that carob gum is a drug. Gum is being studied as a material that carries the active ingredient or regulates its release. The safety of gum as a food additive was re-evaluated by EFSA in 2017; it was concluded that there were no safety concerns in the reported uses for the general population and that there was no need for a numerical acceptable daily intake value (EFSA ANS Panel, 2017).
What is D-Pinitol and How Much is It in Carob?
D-pinitol is a sugar-like compound belonging to the inositol family. It is found in legumes; carob stands out as one of the richest sources of this component. The basics of this subject What is D-Pinitol in Carob? We discussed it in detail in our article.
Tetik et al. (2011), who examined 10 different samples of carob molasses collected from the Turkish market, determined the average D-pinitol content to be approximately 84.6 g/kg at dry weight. The authors stated that carob molasses contains a significant amount of this component compared to other D-pinitol-containing legumes, and that D-pinitol can be used as an indicator in determining adulteration in molasses.
Azab (2022), which compiled D-pinitol from carob, reports that more than thirty biological activities have been reported for the component, among which the most published area is insulin regulation. However, a significant portion of these activities come from cell and animal studies. For the supplement industry, the most important question is what human studies show.
What Do Human Studies Show?
Human studies on D-pinitol do not present a one-way picture. Some studies have had positive results, while others have shown no apparent effect:
| Operation | Participants and implementation | Conclusion |
|---|---|---|
| Davis et al., 2000 | 22 obese, mildly type 2 diabetes or glucose intolerant persons; 28 days of soy-derived pinitol | Blood pinitol level increased; no increase in insulin sensitivity was observed |
| Campbell et al., 2004 | 15 elderly individuals without diabetes; 2 g pinitol daily for 6 weeks | Glucose tolerance and insulin sensitivity were unchanged |
| Kim et al., 2012 | 66 people with type 2 diabetes; 1,200 mg of pinitol or placebo per day in addition to their medication | HbA1c, fasting blood glucose, and HOMA-IR decreased more than placebo |
| Hernández-Mijares et al., 2013 | 30 healthy people; drink containing pinitol from carob, single dose | Only the highest dose (6 g) lowered blood glucose and insulin on a short-term basis |
| Pérez-Piñero et al., 2026 | 52 people with prediabetes; liquid concentrate with carob inositols for 90 days | Improvement in HbA1c and glucose values compared to placebo; no side effects were noted |
There are several reasons for this difference: The groups of participants in the studies (healthy, prediabetic, diabetic), the dose used, the duration, the source of pinitol (soy or carob), and whether the product consists of pinitol alone or more than one inositol and other ingredients. For example, in the study of Kim et al. (2012), participants continued to use diabetes medications; therefore, the result cannot be interpreted as a drug substitute for pinitol.
A systematic review evaluating 15 clinical trials examining the effect of carob and carob products on blood sugar control reached a similar conclusion: In groups with metabolic problems, inositol-rich preparations derived from carob were associated with modest improvements in insulin resistance indicators; however, it has been noted that evidence in type 2 diabetes is limited and often difficult to interpret due to multi-component applications (Victoria-Montesinos et al., 2026).
This table shows that definitive statements such as "lowers blood sugar" or "is good for diabetes" for D-pinitol supplements are not compatible with scientific evidence. Although research has shown some promising results, supplements are not a substitute for treatment; people with diabetes or blood sugar problems should consult their physician before using supplements.
Legislative Framework in Supplementary Products
In Turkey, food supplements are regulated by the Turkish Food Codex Communiqué on Supplementary Foods (Communiqué No: 2013/49), which is under the responsibility of the Ministry of Agriculture and Forestry. The Communiqué defines food supplements as products prepared in forms such as capsules, tablets, powder packages, liquid ampoules of concentrates or extracts of nutrients or herbal and bioactive substances with nutritional or physiological effects in order to supplement normal nutrition, with a determined daily intake dose. According to the Communiqué, herbal ingredients must comply with the plant list published by the Ministry, and other substances must comply with the list of prohibited and restricted substances.
The point underlined by this definition is that food supplements are food, not medicine. Therefore, presenting a supplement containing carob or D-pinitol with the claim of disease prevention or treatment is problematic both scientifically and in terms of legislation.
In products for the European Union market, it is also important whether an ingredient is considered as a traditional food or a "novel food". The European Commission's Novel Food Status Catalogue provides guidance on this issue; however, the Commission clearly states that this catalog is non-binding and not an exhaustive list. For this reason, the current legislation on export-oriented supplement products should be checked on a country-specific basis.
Quality and Standardization Notes for Manufacturers
Carob raw materials for the pharmaceutical and supplement industry expect narrower and better documented specifications compared to food use.
For the carob gamut:
- A specific viscosity range and at what concentration and temperature it is measured
- Moisture, ash and insoluble matter values
- Microbiological limits
- Consistency between batches; It should be noted that differences between different suppliers can affect formula performance
For D-pinitol or carob extract:
- Declaration of D-pinitol content as a percentage and analysis method used
- Clear indication of the source of the extract (carob, soy, etc.)
- Ratio of other sugars and inositols
- Heavy metal, pesticide residue and microbiological analysis
- The daily dose calculation is consistent with the declared content
Since the doses used in clinical studies can be at the gram level, it is of great importance that the product actually contains the declared amount of D-pinitol. Tetik et al.'s (2011) recommendation of D-pinitol in molasses as an indicator of adulteration also points to the value of measurable and verifiable component content.
Frequently Asked Questions
Is carob gum a medicine? Carob gum is an excipient that is being investigated in tablets and gels to regulate the release of the active ingredient or the structure of the product. It is not itself intended as a cure.
Does D-pinitol supplement lower blood sugar? The results of the studies are different. Some human studies showed positive changes, while others did not find any effect. Supplements are not a substitute for treatment; those with blood sugar problems should consult their physician.
Is carob molasses a substitute for D-pinitol supplement? Molasses contains D-pinitol; however, it also contains high amounts of sugar. For this reason, it is not correct to consider molasses as a supplement.
Are food supplements approved like medicine? In Turkey, food supplements are regulated by the Ministry of Agriculture and Forestry within the scope of food legislation; medicines are subject to separate legislation.
Carob Raw Materials with Carob Türkiye
Carob is a raw material that offers both a functional excipient and bioactive components that are the subject of research to the pharmaceutical and supplement industry. The way to position yourself correctly in this field is to clearly define technical specifications and keep health claims within the limits of scientific evidence.
At Carob Türkiye, we supply carob fruit, crumbs, flour/powder, kernels, and extracts. D-Pinitol Extract (Carob Extract), Carob Extract and Carob Seed You can review our pages, for your wholesale and export requests. You can contact us.
This content is for informational purposes only; it is not a substitute for medical advice.
Domestic resources
Republic of Turkey Ministry of Food, Agriculture and Livestock, "Turkish Food Codex Communiqué on Supplementary Foods (Communiqué No: 2013/49)", Official Gazette, 16.08.2013, Number: 28737. lexpera.
com. en/ legislation/ Communiqués/ turk- food- codex- Takviy... Tetik, N., Turhan, İ., Oziyci, H. R., Karhan, M., "Determination of D-pinitol in carob syrup", International Journal of Food Sciences and Nutrition, 62(6), 572–576, 2011 (study conducted in Turkey). doi.
org/ 10. 3109/ 09637486. 2011. 560564 Foreign sources
Dionísio, M., Grenha, A., "Locust bean gum: Exploring its potential for biopharmaceutical applications", Journal of Pharmacy and Bioallied Sciences, 4(3), 175–185, 2012. doi.
org/ 10. 4103/ 0975- 7406. 99013 Sana, S. S., Raorane, C. J., Venkatesan, R. et al., "State-of-the-art progress on locust bean gum polysaccharide for sustainable food packaging and drug delivery applications: A review with prospectives", International Journal of Biological Macromolecules, 275(Pt 1), 133619, 2024. doi.
org/ 10. 1016/ j. ijbiomac. 2024. 133619 Pontes, J. F., Guerreiro, F., Silva, J. P. et al., "Locust bean gum (LBG) – A potential excipient for inhalation purposes: Excipient characterisation and in vitro and in vivo toxicological evaluation", Carbohydrate Polymers, 363, 123729, 2025. doi.
org/ 10. 1016/ j. carbpol. 2025. 123729 EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Mortensen, A. et al., "Re-evaluation of locust bean gum (E 410) as a food additive", EFSA Journal, 15(1), e04646, 2017. doi.
org/ 10. 2903/ j. efsa. 2017. 4646 Azab, A., "D-Pinitol—Active Natural Product from Carob with Notable Insulin Regulation", Nutrients, 14(7), 1453, 2022. doi.
org/ 10. 3390/ nu14071453 Davis, A., Christiansen, M., Horowitz, J. F., Klein, S., Hellerstein, M. K., Ostlund, R. E., "Effect of pinitol treatment on insulin action in subjects with insulin resistance", Diabetes Care, 23(7), 1000–1005, 2000. doi.
org/ 10. 2337/ diacare. 23. 7. 1000 Campbell, W. W., Haub, M. D., Fluckey, J. D. et al., "Pinitol supplementation does not affect insulin-mediated glucose metabolism and muscle insulin receptor content and phosphorylation in older humans", The Journal of Nutrition, 134(11), 2998–3003, 2004. doi.
org/ 10. 1093/ jn/ 134. 11. 2998 Kim, H. J., Park, K. S., Lee, S. K., Min, K. W., Han, K. A., Kim, Y. K., Ku, B. J., "Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus", Annals of Nutrition and Metabolism, 60(1), 1–5, 2012. doi.
org/ 10. 1159/ 000334834 Hernández-Mijares, A., Bañuls, C., Peris, J. E. et al., "A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects", Food Chemistry, 141(2), 1267–1272, 2013. doi.
org/ 10. 1016/ j. foodchem. 2013. 04. 042 Pérez-Piñero, S., Muñoz-Carrillo, J. C., Herrera-Fernández, C. et al., "Effects of Specific Carob (Ceratonia siliqua L.) Liquid Concentrate on Glucose Metabolism in Subjects with Prediabetes: A Randomized Double-Blind Controlled Clinical Trial", Nutrients, 18(10), 1521, 2026. doi.
org/ 10. 3390/ nu18101521 Victoria-Montesinos, D., González-Louzao, R., Barcina-Pérez, P. et al., "Effects of carob (Ceratonia siliqua) and carob-derived products on glycaemic control and insulin resistance: A systematic review of clinical trials", Nutrition Research, 152, 81–98, 2026. doi.
org/ 10. 1016/ j. Nutres. 2026. 05. 007 European Commission, "Novel Food Status Catalogue". food.
Scientific Resourcesec. europa. eu/ food- safety/ novel- food/ novel- food- status...
